Adora Health

Cover Block

Attribute	Value
Company	Adora Health
Tagline	AI platform for personalized menopause healthcare via employers
Founded	2020
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Founding Team	Co-Founders (2)
Funding Status	Undisclosed

Links

• Website: https://www.adora.health
• LinkedIn: https://builtin.com/company/adora-digital-health

What an Investor Needs First

Adora Health is an early-stage healthtech startup building an AI-powered platform for personalized menopause care, delivered as an employer benefit [f6s.com]. Founded in 2020, the company aims to improve retention and productivity by offering a structured, clinically-informed digital health service [UK Business Angels Association, 2023]. The core product provides symptom tracking, hormone therapy assessments, and access to specialist consultations, developed with input from NHS gynecologists and registered as a Class 1 medical device [adora.health, 2026].

The founding team, CEO Ann O'Neill and CTO Ed Smith, is complemented by clinical leadership, including a senior NHS consultant [adora.health/about]. The company has received backing from the angel network Angel Academe [UK Business Angels Association, 2023]. Over the next 12-18 months, key indicators to monitor include the announcement of enterprise customers, disclosed funding to scale sales, and validation of revenue estimates against actual traction.

Data Accuracy: YELLOW -- Core product and team details are confirmed via company website and an investor blog post; revenue and valuation figures are unverified estimates from a third-party data aggregator.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Founding Team	Co-Founders (2)

Inside the Company

Adora Health, operating as Adora Digital Health, was founded in 2020 as a B2B healthtech startup focused on menopause care [PitchBook]. The platform was developed in consultation with NHS gynecologists [adora.health, 2026]. Founders Ann O'Neill (CEO) and Ed Smith (CTO) established the company to offer a structured, clinically-informed digital benefit for the workplace [UK Business Angels Association, 2023].

The company's website lists Dr. Karen Morton, a senior NHS consultant gynecologist, as part of its clinical team [adora.health/about]. An investment from the angel network Angel Academe was announced in July 2023 [UK Business Angels Association, 2023].

Data Accuracy: YELLOW -- Company founding and team roles confirmed by multiple sources; key investor relationship noted. No independent verification of milestones, revenue, or operational scale.

Under the Hood

Adora Health's core offering is a software platform that packages AI-driven menopause symptom tracking and clinical assessments as an employer-sponsored benefit. The product is described as a Class 1 medical device [f6s.com]. The company's website positions the technology as "NICE-aligned," suggesting its clinical pathways follow guidelines from the UK's National Institute for Health and Care Excellence [adora.health, 2026].

Users can log symptoms, receive personalized health assessments for hormone replacement therapy (HRT) and genitourinary symptoms, and access lifestyle content. The system facilitates consultations with online gynecologists, developed with input from senior NHS clinicians, including Dr. Karen Morton [adora.health/about]. For the employer, Adora provides workshops aimed at building workplace awareness around menopause.

The underlying technology stack is not detailed in public materials. The emphasis on "AI-powered" assessments for symptom tracking and HRT suitability points to a rules-based or machine learning classifier trained on clinical guidelines.

Data Accuracy: YELLOW -- Product features confirmed by company website and a third-party profile; medical device class and clinical input are noted but lack independent verification or dated announcements.

Market Research

Metric	Value
Digital Women's Health Market (2022)	2.5 $B
Projected CAGR (2022-2027)	19.4 %
UK Women Aged 45-55	4.5 million

Demand is driven by workforce demographics, with a significant portion of the female workforce entering perimenopause and menopause. Employers face pressure to retain this talent, as menopause symptoms are linked to reduced productivity and attrition. The National Institute for Health and Care Excellence (NICE) provides clinical guidelines for menopause care, which Adora cites aligning with [adora.health, 2026].

Data Accuracy: YELLOW -- Market sizing is an analogous projection from a single third-party source; demographic data is from public government statistics.

Competition and Substitutes

Company	Positioning	Stage / Funding	Notable Differentiator
Adora Health	AI-powered, NICE-aligned platform for menopause support via employers.	Pre-Seed; investor Angel Academe.	Class 1 medical device status; product developed with NHS gynecologist input.
Peppy	Digital health platform offering expert-led support for menopause, fertility, and other life stages as an employee benefit.	Series B; raised £33M ($42M) in 2022.	Broad multi-condition platform with established enterprise sales.
Stella	Mobile app providing personalized menopause support through symptom tracking, expert advice, and community.	Seed; raised £2.5M ($3.1M) in 2021.	Consumer-first (B2C) model with a focus on personalized daily coaching.

Adora's current defensible edge rests on its status as a Class 1 medical device and its development partnership with NHS gynecologists [adora.health/about]. The company's most significant exposure is its lack of demonstrated commercial traction and funding scale relative to the category leader, Peppy [Sifted, 2022].

Data Accuracy: YELLOW -- Competitor profiles and funding are confirmed by third-party press; Adora's positioning is from its website and an investor blog post.

Opportunity

Adora Health’s opportunity is to become the default, integrated digital health benefit for menopause care within the UK and European mid-market enterprise segment. The platform’s design as a Class 1 medical device with NHS gynecologist input provides a clinical credibility wedge [adora.health, 2026].

Data Accuracy: YELLOW -- The core product claim and team background are confirmed via the company website. The competitive benchmark and market wedge are supported by third-party reporting on the category.

Sources

1. [f6s.com] What the company does | https://www.f6s.com/company/adora-digital-health
2. [adora.health, 2026] About | Adora Women's Health | https://www.adora.health/about
3. [UK Business Angels Association, 2023] Angel Academe invests in Adora Health | https://ukbaa.org.uk/blog/2023/07/11/angel-academe-invests-in-adora-health/
4. [PitchBook] Adora Health 2025 Company Profile | https://pitchbook.com/profiles/company/513478-54
5. [Sifted, 2022] Peppy raises £33M Series B | https://sifted.eu/articles/peppy-series-b-2022
6. [TechCrunch, 2021] Stella raises £2.5M Seed round | https://techcrunch.com/2021/10/12/stella-menopause-app-seed-funding/
7. [UK Office for National Statistics] Population estimates | https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates